The Procter & Gamble Company (PGCO34) Fair Value & Analysis
Consumer Defensive · BR · Market cap R$1.7T
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 7 days ago
Share price +8.4% over the past month.
Price vs Fair Value (12 months)
12‑month range R$51.18 – R$64.12 · fair‑value band R$5.04 – R$10.97 · the R$55.93 price screens above the R$7.69 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
The Procter & Gamble Company (PGCO34) currently trades at R$55.93, while our model-based Fair Value estimate is R$7.69 — implying the stock looks roughly 86.3% overvalued today. We read business quality at 72/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, The Procter & Gamble Company generated revenue of R$86.7B at a net margin of 19.2%. Revenue grew 7.4% year over year. It earns a return on equity of 31.1%. Net debt stands at R$25.0B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care segments. The company offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; antiperspirants, deodorants, and personal cleansing products under the Native, Old Spice, Safeguard, and Secret brands; and facial moisturizers, cleaners, and treatments under the Olay and SK-II brands. It also provides blades, razors, shave products, appliances, and other grooming products under the Braun, Gillette, and Venus brands. In addition, the company offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brands; and gastrointestinal, pain relief, rapid diagnostics, respiratory, vitamins/minerals/supplements, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
The Procter & Gamble Company reported revenue of R$84.3B in FY2025 versus R$76.1B in FY2021, a compound +2.6%/yr. Reported net income was R$16.0B in FY2025, compounding +2.8%/yr from FY2021.
Is PGCO34 fairly valued? → Check now
Recent news
- Here is What to Know Beyond Why Procter & Gamble Company (The) (PG) is a Trending Stock
- Exclusive Networks Appoints Sergio Amodeo as Group Chief Financial Officer
- These Household Names Are Dividend Kings. They’re Rock-Solid For Income.
- Native Shakes Up the Body Care Category with New Detoxifying Body Scrub Collection
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| PG PG | 2,590 MXN | 1,415 MXN | -45% |
| L'Oréal S.A LRLCF | $428.02 | $273.79 | -36% |
| Unilever PLC UNLYF | $59.34 | $46.11 | -22% |
| Colgate-Palmolive Company CPA | €77.60 | €36.69 | -53% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,170 | ₹807.38 | -63% |
| Reckitt Benckiser Group RBGLY | $12.32 | $17.37 | +41% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is The Procter & Gamble Company (PGCO34) undervalued?
What is the fair value of PGCO34?
What is the quality score of PGCO34?
What is the revenue of The Procter & Gamble Company (PGCO34)?
What is the net profit margin of PGCO34?
Does The Procter & Gamble Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.